Options for empagliflozin in combination therapy in type 2 diabetes mellitus

International Journal of General Medicine

Volumn 9, Issue , 2016, Pages 155-172

  Hershon, Kenneth S ^a,b  

^a N Shore Diabet and Endocr Assoc   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Combination therapy; DPP 4 inhibitors; Empagliflozin; Metformin; SGLT2 inhibitors; Type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PLACEBO; SULFONYLUREA;

ADD ON THERAPY; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR MORTALITY; CLINICAL TRIAL (TOPIC); DIABETIC KETOACIDOSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EDEMA; FRACTURE; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; KIDNEY DYSFUNCTION; LONG TERM CARE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RISK REDUCTION; TREATMENT DURATION; URINARY TRACT INFECTION;

EID: 84975241233     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/IJGM.S100288     Document Type: Review

References (66)

1. Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract. 2008; 14(6): 782-790.
2. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012; 14(1): 5-14.
3. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014; 8(5): 330-339.
4. INVOKANA® (canagliflozin) tablets for oral use [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2015.
5. FARXIGA® (dapagliflozin) tablets for oral use [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2015.
6. JARDIANCE® (empagliflozin) tablets for oral use [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2015.
7. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardio-vascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22): 2117-2128.
8. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352(9131): 854-865.
9. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366(9493): 1279-1289.
10. Liakos A, Karagiannis T, Athanasiadou E, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014; 16(10): 984-993.
11. Chen M, Xie CG, Gao H, Zheng H, Chen Q, Fang JQ. Comparative effectiveness of sodium-glucose co-transporter 2 inhibitors for controlling hyperglycaemia in patients with type 2 diabetes: protocol for a systematic review and network meta-analysis. BMJ Open. 2016; 6(1): e010252.
12. GLYXAMBI® (empagliflozin and linagliptin) tablets for oral use [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2015.
13. SYNJARDY® (empagliflozin and metformin hydrochloride) tablets for oral use [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2015.
14. European Medicines Agency. Summary of Product Characteristics (June12, 2015): Synjardy (empagliflozin/metformin film-coated tablets). Available from: http: //www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003770/WC500187999.pdf. Accessed September 8, 2015.
15. Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013; 1(3): 208-219.
16. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. A phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013; 15(8): 721-728.
17. Kadowaki T, Haneda M, Inagaki N, et al. Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial. Adv Ther. 2014; 31(6): 621-638.
18. Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013; 15(12): 1154-1160.
19. Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014; 37(6): 1650-1659.
20. Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014; 2(9): 691-700.
21. Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014; 16(2): 147-158.
22. Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013; 36(11): 3396-3404.
23. Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014; 37(7): 1815-1823.
24. Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013; 36(12): 4015-4021.
25. Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015; 38(3): 394-402.
26. DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015; 38(3): 384-393.
27. Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015; 38(3): 420-428.
28. Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014; 2(5): 369-384.
29. Ross S, Thamer C, Cescutti J, Meinicke T, Woerle HJ, Broedl UC. Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2015; 17(7): 699-702.
30. Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015; 17(10): 936-948.
31. American Diabetes Association. Standards of medical care in diabetes (section 7). Approaches to glycemic treatment. Diabetes Care. 2015; 38(Suppl): S41–S48.
32. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyper-glycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38(1): 140-149.
33. ACTOS® (pioglitazone) tablets for oral use [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America, Inc; 2013.
34. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 2012; 55(7): 1953-1962.
35. Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK. Use of antidiabetic drugs in the US, 2003-2012. Diabetes Care. 2014; 37(5): 1367-1374.
36. Oyer D, Cashin K, Gong J. Impact of canagliflozin in type 2 diabetic patients in a real world setting. Endocr Pract. 2015; 21(Suppl 2): 56 (Abstract #264).
37. McGovern AP, Dutta N, Watters K, Munro N, Feher M. Additive weight loss effect with a combination of an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor and a glucagon-like peptide 1 (GLP-1) agonist in Type 2 diabetes. Diabet Med. 2015; 32(S1): 2-3 (Abstract #A6).
38. American Diabetes Association. Standards of medical care in diabetes (section 6). Glycemic targets. Diabetes Care. 2015; 38(Suppl): S33–S40.
39. Esposito K, Cozzolino D, Bellastella G, et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of, 7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2011; 13(7): 594-603.
40. Balkau B, Calvi-Gries F, Freemantle N, Vincent M, Pilorget V, Home PD. Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: the CREDIT study. Diabetes Res Clin Pract. 2015; 108(3): 432-440.
41. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology-clinical practice guidelines for developing a diabetes mellitus comprehensive care plan-2015. Endocr Pract. 2015; 21(0): 1-87.
42. Wilding JP. The importance of weight management in type 2 diabetes mellitus. Int J Clin Pract. 2014; 68(6): 682-691.
43. Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012; 35(4): 731-737.
44. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012; 344: d7771.
45. Cicero AF, Tartagni E, Ertek S. Metformin and its clinical use: new insights for an old drug in clinical practice. Arch Med Sci. 2012; 8(5): 907-917.
46. FDA News Release. FDA Approves Weight-Management Drug Saxenda. December 23, 2014. Silver Spring, MD: Food and Drug Administration. Available from: http: //www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427913.htm. Accessed July 1, 2015.
47. Saxenda Summary of Product Characteristics April 2015. Available from: http: //www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003780/WC500185786.pdf. Accessed June 9, 2015.
48. Bailey RA, Wang Y, Zhu V, Rupnow MF. Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging. BMC Res Notes. 2014; 7: 415.
49. Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4(6): 1121-1127.
50. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013; 36(9): 2508-2515.
51. Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet. 2012; 380(9841): 601-610.
52. American Diabetes Association. Standards of medical care in diabetes (section 8). Cardiovascular disease and risk management. Diabetes Care. 2015; 38(Suppl): S49–S57.
53. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014; 8(4): 262-275.e269.
54. Ferdinand KC, Nasser SA. Racial/ethnic disparities in prevalence and care of patients with type 2 diabetes mellitus. Curr Med Res Opin. 2015; 31(5): 913-923.
55. Kruger DF, LaRue S, Estepa P. Recognition of and steps to mitigate anxiety and fear of pain in injectable diabetes treatment. Diabetes Metab Syndr Obes. 2015; 8: 49-56.
56. Polonsky WH, Hajos TR, Dain MP, Snoek FJ. Are patients with type 2 diabetes reluctant to start insulin therapy? An examination of the scope and underpinnings of psychological insulin resistance in a large, international population. Curr Med Res Opin. 2011; 27(6): 1169-1174.
57. Food and Drug Administration. FDA Drug Safety Communication: FDA Revises Label of Diabetes Drug Canagliflozin (Invokana, Invokamet) to Include Updates on Bone Fracture Risk and New Information on Decreased Bone Mineral Density. Silver Spring, MD: Food and Drug Administration. Available from: http: //www.fda.gov/downloads/Drugs/DrugSafety/UCM461790.pdf. Accessed September 25, 2015.
58. US Food and Drug Administration. Drug Safety Communications (15 May 2015): FDA Warns that SGLT2 Inhibitors for Diabetes may Result in a Serious Condition of too Much Acid in the Blood. Silver Spring, MD: Food and Drug Administration. Available from: http: //www.fda.gov/downloads/Drugs/DrugSafety/UCM446954.pdf. Accessed June 25, 2015.
59. European Medicines Agency. Review of Diabetes Medicines Called SGLT2Inhibitors Started (12 June 2015). Canary Wharf, London: European Medicines Agency. Available from: http: //www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2_inhibitors_20/Procedure_started/WC500187926.pdf. Accessed June 25, 2015.
60. Roach P, Skierczynski P. Euglycemic diabetic ketoacidosis in a patient with type 2 diabetes after treatment with empagliflozin. Diabetes Care. 2016; 39(1): e3.
61. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015; 100(8): 2849-2852.
62. Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014; 103(3): 373-381.
63. Sha S, Polidori D, Farrell K, et al. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study. Diabetes Obes Metab. 2015; 17(2): 188-197.
64. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012; 14(1): 83-90.
65. Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardio-vascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015; 12(2): 90-100.
66. Gilbert RE. The perils of clinical trials. Kidney Int. 2014; 85(4): 745-747.